The FDA has granted clearance on a mobile app that helps clinicians conduct cognitive tests on patients, which may be used to better diagnose post-traumatic stress disorder.
The app, known as DANA (Defense Automated Neurobehavioral Assessment), was developed by AnthroTronix and developed in part from funding from the Department of Defense. The technology has already been used in the field to evaluate service members deployed in Afghanistan.
DANA will be available as an app for both tablets and phone, and works with both Android and Apple iOS operating systems.
The company says the assessment DANA provides will be both cognitive and psychological. “The combination of these allows providers insight into the prevalence of symptoms related to both traumatic brain injuries and PTSD,” AnthroTronix said on its website.
Results DANA gathers “are evaluated by a qualified health professional who can assess factors that may affect measurement of reaction time such as concussion, dementia, post-traumatic stress, depression, stress, fatigue, prescription and non-prescription medications, and some nutritional supplements, among others,” the company told MobiHealthNews.
Last week the FDA granted 510(k) clearance to a mobile-based cognitive test called DANA(Defense Automated Neurobehavioral Assessment), which helps healthcareproviders better assess the medical or psychological state of theirpatients.
DANA was developed by Silver Spring, Maryland-basedAnthroTronix, a digital health R&D company, and it was developedpartially thanks to funding from the US Navy Bureau of Medicine andSurgery as well as a Rapid Innovation Fund award from the US Army.
Thelatter led to DANA being used to help evaluate the medical status, including possible post-traumatic stress disorder, ofdeployed military service members in Afghanistan.
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Evidence-Based Guidance
- Conference Coverage
- Unique Psychiatry Case Studies
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.
From Mobihealthnews
